16. クロウ・深瀬症候群 Crow-Fukase syndrome Clinical trials / Disease details
臨床試験数 : 13 / 薬物数 : 18 - (DrugBank : 8) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 81
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04396496 (ClinicalTrials.gov) | September 22, 2020 | 15/5/2020 | Treatment of POEMS Syndrome With Daratumumab | A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab | POEMS Syndrome | Drug: Daratumumab Injection | University of Arkansas | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |